Serious liver injury. Leading reason for drug removals, restrictions.
Meadows
M
M
D016907:Adverse Drug Reaction Reporting Systems; D000700:Analgesics / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects; D001577:Benzophenones / Q000009:adverse effects; D001969:Bromobenzenes / Q000009:adverse effects; D002599:Chalcone / Q000009:adverse effects / Q000031:analogs & derivatives*; D047188:Chalcones; D002839:Chromans / Q000009:adverse effects; D017277:Drug Approval; D004338:Drug Combinations; D024841:Fluoroquinolones; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D017093:Liver Failure / Q000139:chemically induced*; D008111:Liver Function Tests; D009287:Naphthyridines / Q000009:adverse effects; D010636:Phenols / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D013844:Thiazoles / Q000009:adverse effects; D045162:Thiazolidinediones; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration
D000700:Analgesics; D000890:Anti-Infective Agents; D001577:Benzophenones; D001969:Bromobenzenes; D047188:Chalcones; D002839:Chromans; D004338:Drug Combinations; D024841:Fluoroquinolones; D007004:Hypoglycemic Agents; D009287:Naphthyridines; D010636:Phenols; D013844:Thiazoles; D045162:Thiazolidinediones; C075560:alatachalcone; D002599:Chalcone; C053083:bromfenac; C080163:trovafloxacin; D000077288:Troglitazone